<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01019161</url>
  </required_header>
  <id_info>
    <org_study_id>D1531C00012</org_study_id>
    <nct_id>NCT01019161</nct_id>
  </id_info>
  <brief_title>An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)</brief_title>
  <official_title>A Phase I Open, Non-randomised, Single-centre Study to Assess the Metabolism, Excretion and Pharmacokinetics of AZD1152 and AZD1152 hQPA Following Intravenous Administration of [14C]-AZD1152 in Patients With Acute Myeloid Leukaemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess how AZD1152 is absorbed or excreted in and out of the
      body in patients with Acute Myeloid Leukaemia (AML).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The concentration of total radioactivity, AZD1152 and AZD1152 hQPA in plasma and their ratios, the concentration of total radioactivity in blood and its blood/plasma concentration ratios</measure>
    <time_frame>Day1-10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The derived plasma and urinary pharmacokinetic parameters for AZD1152 and AZD1152 hQPA The percentage of the [14C] AZD1152 dose recovered in urine, faeces and vomit (if presented), and the percentage of radioactive dose recovered overall.</measure>
    <time_frame>Day1-10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs), serious adverse events (SAEs) and deaths, Discontinuations for tolerability reasons, vital signs (temperature, blood pressure [BP], pulse rate and respiratory rate [RR])</measure>
    <time_frame>AEs, SAEs, deaths, discontinuations ongoing to completion and vitals over 22 days - Screening, PD Day 1, Days 3, 6, 9, 14, 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (ECG) parameters</measure>
    <time_frame>Screening, PD Day 1, Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical chemistry, haematology (including clotting parameters) and urinalysis; physical examination</measure>
    <time_frame>Chemistry/Heamatology - Screening, PD Day 1, Days 3, 6, 9, 14, 22Urinalysis - Screening, PD Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Acute Myeloid Leukaemia</condition>
  <arm_group>
    <arm_group_label>AZD1152</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg Lyophile 5 mL Diluent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C14 AZD1152</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1152 radiolabelled IV solution. 1.05 mg/ml will be presented as a 15 ml fill in a 20 ml vial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1152</intervention_name>
    <description>100mg Lyophile, 5mL Diluent IV infusion</description>
    <arm_group_label>AZD1152</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C14 AZD1152</intervention_name>
    <description>radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion</description>
    <arm_group_label>C14 AZD1152</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with relapsed or refractory AML for which no standard therapies are
             anticipated to result in durable remission. Or, patients with newly diagnosed AML who
             are not considered to be suitable for standard induction and consolidation
             chemotherapy

          -  Ability to stay in hospital for up to 9 days on the [14C] AZD1152 treatment cycle.

          -  Subjects who have relapsed &gt; 1 year following myeloablative therapy with allogeneic
             bone marrow or stem cell transplantation may be eligible if they have no or limited
             evidence of extensive graft-versus-host disease

        Exclusion Criteria:

          -  QTc interval â‰¥470 ms calculated from a single ECG reading or a mean of 3 ECG readings
             using Fridericia's or Bazett's correction

          -  Administration of hydroxyurea to control peripheral blood counts is prohibited within
             24 hours prior to first dose of study drug

          -  Any chemotherapy or radiotherapy within 14 days prior to starting the study (not
             including palliative radiotherapy at focal sites)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Dennis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christie Hospital, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2009</study_first_submitted>
  <study_first_submitted_qc>November 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>October 19, 2010</last_update_submitted>
  <last_update_submitted_qc>October 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Acute Myeloid Leukaemia (AML)</keyword>
  <keyword>AML</keyword>
  <keyword>AZD1152</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

